News – Page 3 – www.brainwork.md

9th July 2019

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Natalizumab.jpg 3067 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

Michael Furrer, PhD
0
0

9th July 2019

Serum NfL levels shine a light on neuroaxonal damage and disease

https://www.brainwork.md/content/uploads/2019/07/Brainwork-NfL.jpg 4089 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

Michael Furrer, PhD
0
0

9th July 2019

Cellular power failures linked to Parkinsonism

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Parkinsonism.jpg 3150 2100 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 9th July 2019 9th July 2019

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

Mea Holm, PhD
0
0

4th July 2019

8-year follow-up data of alemtuzumab presented

https://www.brainwork.md/content/uploads/2019/07/follow-up-data-of-alemtuzumab-presented-image.jpg 1920 1280 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 4th July 2019 9th July 2019

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

Michael Furrer, PhD
0
0

1st July 2019

Thought-controlled prosthetic limbs could be in reach

https://www.brainwork.md/content/uploads/2019/07/Brainwork-ProstheticLimb.jpg 3446 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 1st July 2019 15th July 2019

Improvements in the way in which neural activity is mapped could be an important step towards thought-controlled body augmentations such as prosthetic limbs, researchers at the Neural Prosthetics Translational Laboratory…

Peter Stevenson, PhD
0
0

20th June 2019

Machine-learning algorithm predicts psychosis from speech

https://www.brainwork.md/content/uploads/2019/06/Brainwork-MachineLearning.jpg 3150 2100 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 20th June 2019 19th June 2019

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

Peter Stevenson, PhD
0
0

17th May 2019

Shedding light on CIDP

https://www.brainwork.md/content/uploads/2019/05/MPR585-Brainwork-AAN-V00-03-20190509-01.jpg 1920 1080 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 31st May 2019

While it is the most common chronic autoimmune neuropathy, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired peripheral neuropathy characterised by proximal upper and lower limb weakness. CIDP remains…

Carlotta Foletti, PhD
0
0

17th May 2019

Establishing sNfL as an MS Biomarker

https://www.brainwork.md/content/uploads/2019/05/Brainwork-MSBiomarkers.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

Carlotta Foletti, PhD
0
0

17th May 2019

News from the ocrelizumab front

https://www.brainwork.md/content/uploads/2019/05/Brainwork-NewsOcrelizumab.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

Carlotta Foletti, PhD
0
0

17th May 2019

Latest advances in migraine therapy

https://www.brainwork.md/content/uploads/2019/05/Brainwork-MigraineTreatment.jpg 3682 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

Migraines are the most common type of primary headache disorders, and triptans – serotonin 5-HT1B/1D receptor agonists originally developed as cranial vasoconstrictors – are the backbone of current acute attack…

Carlotta Foletti, PhD
0
0